Acrobiosystems Co Ltd
SZSE:301080

Watchlist Manager
Acrobiosystems Co Ltd Logo
Acrobiosystems Co Ltd
SZSE:301080
Watchlist
Price: 42.81 CNY -3.91% Market Closed
Market Cap: 5.1B CNY
Have any thoughts about
Acrobiosystems Co Ltd?
Write Note

Acrobiosystems Co Ltd
Change in Working Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Acrobiosystems Co Ltd
Change in Working Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Change in Working Capital CAGR 3Y CAGR 5Y CAGR 10Y
Acrobiosystems Co Ltd
SZSE:301080
Change in Working Capital
-ÂĄ392.6m
CAGR 3-Years
-65%
CAGR 5-Years
-51%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Change in Working Capital
-ÂĄ12.8B
CAGR 3-Years
-278%
CAGR 5-Years
-54%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Change in Working Capital
ÂĄ558m
CAGR 3-Years
N/A
CAGR 5-Years
78%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Change in Working Capital
-ÂĄ3.9B
CAGR 3-Years
-70%
CAGR 5-Years
-51%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Change in Working Capital
-ÂĄ3.9B
CAGR 3-Years
-26%
CAGR 5-Years
-24%
CAGR 10-Years
-32%
Imeik Technology Development Co Ltd
SZSE:300896
Change in Working Capital
-ÂĄ496.4m
CAGR 3-Years
-43%
CAGR 5-Years
-30%
CAGR 10-Years
N/A
No Stocks Found

Acrobiosystems Co Ltd
Glance View

Market Cap
5.1B CNY
Industry
Biotechnology

ACROBiosystems Co., Ltd. engages in the development of biomedicine and bio-protein technology. The company is headquartered in Beijing, Beijing and currently employs 397 full-time employees. The company went IPO on 2021-10-18. The firm's main products are recombinant proteins and detection services, as well as kits, antibodies, fillers, culture media and other related products. The firm's main products and services are applied to research and development (R&D) and production links such as early drug discovery and verification, drug screening and optimization, development and optimization of diagnostic reagents, preclinical and clinical trials, drug production process and process control (CMC) of tumors, autoimmune diseases, cardiovascular diseases, infectious diseases and other diseases.

Intrinsic Value
50.12 CNY
Undervaluation 15%
Intrinsic Value
Price

See Also

What is Acrobiosystems Co Ltd's Change in Working Capital?
Change in Working Capital
-392.6m CNY

Based on the financial report for Dec 31, 2023, Acrobiosystems Co Ltd's Change in Working Capital amounts to -392.6m CNY.

What is Acrobiosystems Co Ltd's Change in Working Capital growth rate?
Change in Working Capital CAGR 5Y
-51%

Over the last year, the Change in Working Capital growth was -59%. The average annual Change in Working Capital growth rates for Acrobiosystems Co Ltd have been -65% over the past three years , -51% over the past five years .

Back to Top